Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates

Anika Therapeutics (ANIK) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of$ 0.30. This compares to loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -183.33%. A quarter ago, it was expected that this medical technology company would post earnings of$ 0.23 per share when it actually produced earnings of $0.17, delivering a surprise of -26.09%.Over the last four quarters, the c ...